333 related articles for article (PubMed ID: 27841032)
1. Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.
Espinós JJ; Vanrell C; Gich I; Urgell E; Calaf J
Gynecol Endocrinol; 2017 Feb; 33(2):148-151. PubMed ID: 27841032
[TBL] [Abstract][Full Text] [Related]
2. Importance of macroprolactinemia in hyperprolactinemia.
Kasum M; Pavičić-Baldani D; Stanić P; Orešković S; Sarić JM; Blajić J; Juras J
Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():28-32. PubMed ID: 25461348
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
[TBL] [Abstract][Full Text] [Related]
4. A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):223-228. PubMed ID: 27750350
[No Abstract] [Full Text] [Related]
5. Prevalence and reproductive manifestations of macroprolactinemia.
Kalsi AK; Halder A; Jain M; Chaturvedi PK; Sharma JB
Endocrine; 2019 Feb; 63(2):332-340. PubMed ID: 30269265
[TBL] [Abstract][Full Text] [Related]
6. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
[TBL] [Abstract][Full Text] [Related]
7. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia.
Kasum M; Orešković S; Čehić E; Šunj M; Lila A; Ejubović E
Taiwan J Obstet Gynecol; 2017 Dec; 56(6):719-724. PubMed ID: 29241908
[TBL] [Abstract][Full Text] [Related]
8. Macroprolactinemia in women with hyperprolactinemia: a 10-year follow-up.
Radavelli-Bagatini S; Lhullier FL; Mallmann ES; Spritzer PM
Neuro Endocrinol Lett; 2013; 34(3):207-11. PubMed ID: 23685418
[TBL] [Abstract][Full Text] [Related]
9. Frequency of Macroprolactin in Hyperprolactinemia.
Sherazi NA; Baig MZ; Khan AH
J Coll Physicians Surg Pak; 2018 Feb; 28(2):93-97. PubMed ID: 29394965
[TBL] [Abstract][Full Text] [Related]
10. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia.
Overgaard M; Pedersen SM
Clin Chem Lab Med; 2017 Oct; 55(11):1744-1753. PubMed ID: 28236625
[TBL] [Abstract][Full Text] [Related]
11. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.
Tamer G; Telci A; Mert M; Uzum AK; Aral F; Tanakol R; Yarman S; Boztepe H; Colak N; Alagöl F
Endocrine; 2012 Feb; 41(1):138-43. PubMed ID: 21959531
[TBL] [Abstract][Full Text] [Related]
13. Screening for macroprolactinaemia and pituitary imaging studies.
Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
[TBL] [Abstract][Full Text] [Related]
14. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
Lu CC; Hsieh CJ
Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536
[TBL] [Abstract][Full Text] [Related]
15. [The reaction of the hypophysis to thyroliberin and metoclopramide in women with hyperprolactinemia].
Tkachenko NN; Potin VV; Beskrovnyĭ SV; Nosova LG
Probl Endokrinol (Mosk); 1990; 36(2):35-40. PubMed ID: 2114023
[TBL] [Abstract][Full Text] [Related]
16. Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center.
Chutpiboonwat P; Yenpinyosuk K; Sridama V; Kunjan S; Klaimukh K; Snabboon T
Pan Afr Med J; 2020; 36():8. PubMed ID: 32550971
[TBL] [Abstract][Full Text] [Related]
17. Prolactin response to metoclopramide and thyrotropin-releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity.
Bussen S; Brosemann N; Steck T
Gynecol Endocrinol; 1996 Apr; 10(2):83-90. PubMed ID: 8701791
[TBL] [Abstract][Full Text] [Related]
18. Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia.
Hattori N; Nakayama Y; Kitagawa K; Li T; Inagaki C
Endocrinology; 2007 May; 148(5):2465-70. PubMed ID: 17303669
[TBL] [Abstract][Full Text] [Related]
19. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121
[TBL] [Abstract][Full Text] [Related]
20. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin.
Hu Y; Ni J; Zhang B; Cheng W; Zhang H; Ye H; Ji L; Lu B; Guan M
BMC Endocr Disord; 2021 Oct; 21(1):197. PubMed ID: 34620143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
